Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-09-25T00:15:59.198Z.
Calculation as of: 2026-09-25T00:15:59.198Z.
Quote observation: 2026-09-24T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d36a9ef3dd00a3b0176393925906ed0ad09061a29621a98fe511a29c7f47a262
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$33.40B
Price/FCF Ratio
61.56
TTM Avg
131.20
3Y Avg
460.90
5Y Avg
460.90
Market Cap
$30.70B
Price/FCF Ratio
35.53
TTM Avg
31.88
3Y Avg
30.98
5Y Avg
35.29
Market Cap
$29.98B
Price/FCF Ratio
33.50
TTM Avg
24.30
3Y Avg
23.00
5Y Avg
23.26
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ResMed Inc. (RMD) | $32.19B | N/A | N/A | N/A | N/A |
| Alcon Inc. (ALC)vs › | $31.49B | 18.71 | 23.50 | 40.25 | 87.45 |
| DexCom, Inc. (DXCM)vs › | $33.01B | 23.49 | 27.06 | 56.23 | 159.53 |
| Alnylam Pharmaceuticals, Inc. (ALNY)vs › | $33.40B | 61.56 | 131.20 | 460.90 | 460.90 |
| Biogen Inc. (BIIB)vs › | $33.45B | 12.40 | 11.53 | 17.02 | 18.15 |
| Mettler-Toledo International Inc. (MTD)vs › | $30.70B | 35.53 | 31.88 | 30.98 | 35.29 |
| Centene Corp. (CNC)vs › | $30.58B | 3.41 | 6.40 | 22.74 | 16.79 |
| GE HealthCare Technologies Inc. (GEHC)vs › | $29.98B | 33.50 | 24.30 | 23.00 | 23.26 |
| Zoetis Inc. (ZTS)vs › | $29.48B | 12.46 | 21.56 | 35.56 | 43.55 |
| Medline Inc. (MDLN)vs › | $29.31B | 21.84 | 19.63 | 19.63 | 19.63 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
